Bryce Point Capital LLC Buys Shares of 25,574 Dynavax Technologies Corporation (NASDAQ:DVAX)

Key Points

• Bryce Point Capital LLC has invested approximately $357,000 in Dynavax Technologies Corporation (NASDAQ:DVAX), acquiring 25,574 shares in the first quarter.
• Dynavax Technologies reported a loss of $0.11 EPS for the last quarter, missing expectations of $0.03, with revenues of $68.16 million, below the $70.01 million forecast.
• Research analysts have issued mixed ratings on DVAX stock, with one downgrade to a "hold" rating and a lowered price target from $12.00 to $10.00 by Goldman Sachs.

Bryce Point Capital LLC purchased a new stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 25,574 shares of the biopharmaceutical company's stock, valued at approximately $357,000.

Several other large investors have also recently added to or reduced their stakes in DVAX. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Dynavax Technologies by 4.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company's stock valued at $401,000 after buying an additional 1,453 shares during the period. Pacer Advisors Inc. acquired a new position in shares of Dynavax Technologies during the first quarter valued at approximately $292,000. Choreo LLC increased its position in shares of Dynavax Technologies by 3.2% during the 1st quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company's stock valued at $452,000 after purchasing an additional 1,065 shares during the period. Moloney Securities Asset Management LLC acquired a new position in shares of Dynavax Technologies during the 1st quarter valued at $131,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of Dynavax Technologies during the 1st quarter valued at $30,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on DVAX. The Goldman Sachs Group dropped their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. Wall Street Zen cut shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Finally, JMP Securities decreased their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Trading Down 1.3%

DVAX traded down $0.15 during trading on Thursday, reaching $11.02. The company had a trading volume of 546,403 shares, compared to its average volume of 2,117,061. The firm's 50-day simple moving average is $10.33 and its 200 day simple moving average is $11.63. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -21.22 and a beta of 1.03. The company has a debt-to-equity ratio of 0.49, a quick ratio of 10.84 and a current ratio of 11.93. Dynavax Technologies Corporation has a 12-month low of $9.22 and a 12-month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. The firm had revenue of $68.16 million for the quarter, compared to analysts' expectations of $70.01 million. Equities research analysts anticipate that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.